S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Biden To Unleash "Choke Point" Operation On America? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
3 Free Stock Picks per Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
3 Free Stock Picks per Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Biden To Unleash "Choke Point" Operation On America? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
3 Free Stock Picks per Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
3 Free Stock Picks per Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Biden To Unleash "Choke Point" Operation On America? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
3 Free Stock Picks per Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
3 Free Stock Picks per Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Biden To Unleash "Choke Point" Operation On America? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
3 Free Stock Picks per Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
3 Free Stock Picks per Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
Positive News SentimentPositive News
NASDAQ:VCYT

Veracyte (VCYT) Competitors

$25.58
+0.09 (+0.35%)
(As of 05/26/2023 ET)
Compare
Today's Range
$25.17
▼
$26.10
50-Day Range
$20.58
▼
$26.29
52-Week Range
$14.92
▼
$32.40
Volume
504,293 shs
Average Volume
688,831 shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.20
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

VCYT vs. RDNT, FLGT, VRDN, PROG, GH, CSTL, NTRA, SUPN, TNDM, and PCRX

Should you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include RadNet (RDNT), Fulgent Genetics (FLGT), Viridian Therapeutics (VRDN), Progenity (PROG), Guardant Health (GH), Castle Biosciences (CSTL), Natera (NTRA), Supernus Pharmaceuticals (SUPN), Tandem Diabetes Care (TNDM), and Pacira BioSciences (PCRX). These companies are all part of the "medical" sector.

Veracyte vs.

Veracyte (NASDAQ:VCYT) and RadNet (NASDAQ:RDNT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

RadNet has higher revenue and earnings than Veracyte. RadNet is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$296.54 million6.25-$36.56 million-$0.41-62.39
RadNet$1.43 billion1.18$10.65 million-$0.24-120.49

68.3% of RadNet shares are held by institutional investors. 2.9% of Veracyte shares are held by insiders. Comparatively, 5.1% of RadNet shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Veracyte and Veracyte both had 6 articles in the media. Veracyte's average media sentiment score of 1.51 beat RadNet's score of 0.64 indicating that Veracyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
5 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
RadNet
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Veracyte presently has a consensus price target of $30.20, indicating a potential upside of 18.06%. RadNet has a consensus price target of $30.00, indicating a potential upside of 3.73%. Given Veracyte's higher probable upside, equities research analysts plainly believe Veracyte is more favorable than RadNet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
RadNet
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Veracyte has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, RadNet has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

Veracyte received 88 more outperform votes than RadNet when rated by MarketBeat users. Likewise, 73.14% of users gave Veracyte an outperform vote while only 67.20% of users gave RadNet an outperform vote.

CompanyUnderperformOutperform
VeracyteOutperform Votes
422
73.14%
Underperform Votes
155
26.86%
RadNetOutperform Votes
334
67.20%
Underperform Votes
163
32.80%

RadNet has a net margin of -0.90% compared to Veracyte's net margin of -9.70%. RadNet's return on equity of 3.28% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte -9.70% -2.83% -2.63%
RadNet -0.90% 3.28% 0.67%

Summary

RadNet beats Veracyte on 10 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VCYT vs. The Competition

Export to Excel
MetricVeracyteMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$1.85B$1.69B$4.57B$6.18B
Dividend YieldN/A2.78%2.32%6.15%
P/E Ratio-62.399.77113.1014.42
Price / Sales6.2551.013,697.9586.33
Price / CashN/A7.1398.16107.27
Price / Book1.712.685.047.13
Net Income-$36.56M-$107.09M$118.58M$192.91M
7 Day Performance4.88%-4.00%1.10%0.20%
1 Month Performance12.99%-4.99%1.28%1.33%
1 Year Performance35.42%-3.80%19.56%-0.24%

Veracyte Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RDNT
RadNet
1.9682 of 5 stars		$28.37
+1.1%		$30.00
+5.7%		+39.1%$1.66B$1.43B-118.209,067Insider Selling
FLGT
Fulgent Genetics
1.9421 of 5 stars		$40.25
+0.4%		$42.33
+5.2%		-32.1%$1.20B$618.97M-45.221,012Short Interest ↑
VRDN
Viridian Therapeutics
2.2312 of 5 stars		$24.88
+0.5%		$45.08
+81.2%		+94.7%$1.07B$1.77M-5.3450Short Interest ↑
PROG
Progenity
0 of 5 stars		$3.97
-18.1%		N/A+410.3%$731.27M$1.25M-1.41124
GH
Guardant Health
2.419 of 5 stars		$29.79
-3.3%		$55.80
+87.3%		-34.7%$3.06B$449.54M-4.591,793Analyst Upgrade
Short Interest ↑
News Coverage
High Trading Volume
CSTL
Castle Biosciences
2.4137 of 5 stars		$25.82
+3.3%		$44.67
+73.0%		+14.6%$689.14M$137.04M-9.53342Short Interest ↓
News Coverage
Positive News
NTRA
Natera
2.17 of 5 stars		$51.92
-2.2%		$74.89
+44.2%		+18.0%$5.93B$820.22M-9.703,018Short Interest ↑
SUPN
Supernus Pharmaceuticals
2.6149 of 5 stars		$34.06
-1.3%		$46.00
+35.1%		+18.4%$1.88B$668.50M38.27575Positive News
TNDM
Tandem Diabetes Care
2.2734 of 5 stars		$29.40
-0.8%		$53.14
+80.8%		-62.5%$1.90B$801.22M-9.272,600Positive News
PCRX
Pacira BioSciences
2.2665 of 5 stars		$41.52
+0.1%		$62.73
+51.1%		-38.8%$1.91B$666.82M-153.78697Positive News

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:VCYT) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -